Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa  

Forest expects its Alzheimer's drug memantine to be approved for moderate to severe disease in the spring of 2004, Chief Operating Officer Kenneth Goodman said during a fiscal 2003 fourth quarter earnings call April 22